微创 fellowship 培训的肝胆胰外科医生:微创胰十二指肠切除术治疗壶腹周围肿瘤结局是否优于开放手术?
该研究回顾性分析了一位接受微创肝胆胰 fellowship 培训的医生 10 年间实施的 100 例胰十二指肠切除术(57 例微创,43 例开放),其中恶性壶腹周围肿瘤亚组分析显示微创组估计平均出血量和住院时间更少,但手术时间更长;两组 30/90 天死亡率和并发症率无统计学差异,R0 切除率无统计学差异,但微创组总生存和无复发生存均优于开放组。
要点
- 微创胰十二指肠切除术治疗壶腹周围肿瘤可减少出血量和住院时间。
- 微创组手术时间更长,但死亡率和并发症率与开放组无统计学差异。
- 微创组总生存和无复发生存优于开放组,但需注意选择偏倚。
核心结论
- 接受微创和开放手术双重培训的肝胆胰外科医生可能优先选择微创方式治疗可切除壶腹周围肿瘤。
- 微创胰十二指肠切除术可减少出血量和住院时间,尽管手术时间更长,但可能提高 R0 切除率并最终改善生存。
研究设计与样本
- 回顾性综述一位微创肝胆胰 fellowship 培训医生 10 年间实施的 100 例胰十二指肠切除术(57 例微创,43 例开放)。
- 对恶性壶腹周围肿瘤进行亚组分析(微创组 vs 开放组),主要终点为术后死亡率和并发症率。
主要发现
- 微创组恶性壶腹周围肿瘤估计平均出血量 345 mL,开放组 971 mL,p < 0.001。
- 微创组平均住院时间 12 天,开放组 16 天,p = 0.007。
- 微创组平均手术时间 456 分钟,开放组 371 分钟,p < 0.001。
- 微创组 30 天和 90 天死亡率分别为 2.6% 和 5.1%,开放组分别为 0% 和 3.2%,p = 1。
- 微创组 30 天和 90 天并发症率分别为 41.0% 和 43.6%,开放组分别为 35.5% 和 41.9%,p = 0.8 和 p = 1。
临床怎么用
- 对于可切除壶腹周围肿瘤,接受过微创和开放手术培训的肝胆胰外科医生可优先考虑微创胰十二指肠切除术。
- 微创胰十二指肠切除术虽手术时间较长,但可减少出血量和住院时间,且不增加死亡率和并发症率。
- 微创技术可能提高 R0 切除率并改善生存,但需结合辅助化疗的及时启动。
局限性
- 回顾性单术者经验,样本量有限,存在选择偏倚。
- 开放组 borderline 可切除胰腺导管腺癌患者比例高于微创组(8 例 vs 2 例,p = 0.07)。
- 生存获益可能受选择偏倚和辅助治疗差异影响,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although early series focused on benign disease, minimally invasive pancreatoduodenectomy (MIPD) might be particularly suited for malignancy. Unlike their predecessors, fellowship-trained (FT) Hepatic-Pancreatic and Biliary (HPB) surgeons usually have equal skills in approaching peri-ampullary tumors (PT) either openly or via minimally invasive (MI) techniques. METHOD: We retrospectively reviewed a MI-HPB-FT surgeon's 10-year experience with PD. A sub-analysis of malignant PT was also done (MIPD-PT vs. OPD-PT). The primary endpoint was to assess postoperative mortality and morbidity. Secondary endpoints included operative parameters, length of hospital stay, and survival analysis. Moreover, we addressed practice pattern changes for a surgeon straight out of training with no previous experience of independent surgery. RESULTS: From December 2007-February 2018, one MI-HPB-FT performed a total of 100 PDs, including 57 MIPDs and 43 open PDs (OPDs). In both groups, over 70% of PDs were undertaken for malignancy. Eight patients with borderline resectable pancreatic ductal cancer (PDC) were in the OPD-PT group (as compared to only 2 in the MIPD-PT group) (p = 0.07). Estimated mean blood loss and length of stay were less in the MIPD-PT group (345 mL and 12 days) as compared to the OPD-PT group (971 mL and 16 days), p < 0.001 and p = 0.007, respectively. However, the mean operative time was longer for the MIPD-PT (456 min) as compared to the OPD-PT (371 min), p < 0.001. Thirty and 90-day mortality was 2.6%/5.1% after MIPD-PT compared to 0%/3.2% after OPD-PT, respectively, p = 1. Overall 30-/90-day morbidity rates were similar at 41.0%/43.6% after MIPD-PT and 35.5%/41.9% after OPD-PT, respectively, p = 0.8 and 1. Complete resection (R0) rates were not statistically different, 97.4% after MIPD-PT compared to 87.0% after OPD-PT (p = 0.2). After MIPD and OPD for malignant PT, overall 1, 3 and 5-year survival rates, and median survival were 82.5%, 59.6% and 46.3% and 38 months as compared to 52.5%, 15.7% and 10.5% and 13 months, respectively (p = 0.01). In the MIDP-PT group, recurrence free survival (RFS) at 1, 3 and 5 years and median RFS were 69.1%, 41.9% and 33.5% and 26 months as compared to 50.4%, 6.3% and 6.3% and 13 months, in the OPD-PT group, respectively (p = 0.03). CONCLUSION: FT HPB Surgeons who begin their practice with the ability to do both MI and OPD may preferentially approach resectable peri-ampullary tumors minimally invasively. This may result in decreased blood loss decreased length of hospital stays. Despite longer operative time, the improved visualization of MI techniques may enable superior R0 rates when compared to historical open controls. Moreover, combined with quicker initiation of adjuvant chemotherapeutic treatments, this may eventually result in improved survival.
引用
- Gumbs AA, Chouillard E, Abu Hilal M, et al. The experience of the minimally invasive (MI) fellowship-trained (FT) hepatic-pancreatic and biliary (HPB) surgeon: could the outcome of MI pancreatoduodenectomy for peri-ampullary tumors be better than open? Surg Endosc. 2020. PMID: 33146810. doi:10.1007/s00464-020-08118-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。